IV Fluid Disruption Information
REcommendations, resources, & updates regarding the current IV fluid disruption From Hurricane Helene.
For questions, please reach out to us at R7DHRE@unmc.edu
Let us know how your facility is being affected!
-
FDA Update: To address the current drug shortage, B. Braun is releasing 12 lots of sodium chloride 0.9% (500ml and 1000ml). These lots are associated with primary air volume (headspace) below specification limit which could impact container fluid level monitoring during use.
Baxter Updates (updated weekly by Baxter)
12.05.24:
Baxter is making continued strong progress at our North Cove site, including the initial resumption this week of the following:
All 3L irrigation manufacturing lines
All peritoneal dialysis (PD) solutions manufacturing lines
Note that while production on these lines has restarted, it will take some time for the lines to ramp up and produce at pre-hurricane levels.
Baxter communicated details on allocation increases for several IV product groups to U.S. customers and distributors effective Nov. 26.
11.21.24:
Baxter expects to communicate details on the next planned allocation increases to U.S. customers on Nov. 25th.
Baxter released the first product (1L IV solutions) that was manufactured post-hurricane.
ASPR Coordinates Airlift Operation to Increase Access and Supply of IV Fluids (10.19.24)
-
Multiple facilities, with varying levels of concern, have indicated that the temporary closure of a Baxter manufacturing plant in Marion, N.C., because of damage from Hurricane Helene may impact the supply chain. Conservation and contingency strategies are likely to be needed.
This Baxter facility is a critical supplier of intravenous and peritoneal dialysis solutions, producing approximately 60% of the IV solutions used domestically. Baxter is actively working on remediation efforts and exploring alternative production sites to mitigate the impact. Some alternative vendors have put customers on allocation for protective reasons but intend to ramp up production to mitigate these challenges.
ASPR and the FDA are actively working with alternate manufacturers to increase output. Baxter currently has 500 personnel on site for remediation and expects that number to double next week. -
The disruption in supply of these items may impact patient care. A current inventory and use rate of these items can clarify which conservation strategies will prove most helpful. Per Baxter, the current estimate is for this disruption to last 3 months.
Use this spreadsheet, based on your historical data, to determine how many days your current supply will last.
-
Use this spreadsheet, based on your historical data, to determine how many days your current supply will last.
Rehydration Therapy (EMR Build)
ASHP
ASPR
FDA
Vizient
Conservation Support Resources
Intravenous Solution Conservation Strategies, American Society of Health-System Pharmacists (ASHP)
ISMP Safe Practice Guidelines for Adult IV Push Medications 2015
ATS Clinical Recommendations: 10 Steps for Hospitals Facing Intravenous Fluid Shortages 2017
Saline flush and vial shortage, Infusion Nurses Society 2021
Saline Shortages – Many Causes, No Simple Solution NEJM 2018
ASA Suggested Actions on Conservation of IV Solutions During Ongoing Shortage
Interim Strategies of Peritoneal Dialysis Solution Use for Prevalent Patients Undergoing PD
-
Baxer Updates:
11.14.24:
Second IV solutions manufacturing line restarted
Peritoneal dialysis solutions and irrigation will be next 2 lines to restart in early December
2nd temporary bridge installed at site
10.31.24: Baxter Restarts busiest IV solutions manufacturing line
FDA: Hurricane Helene: Baxter’s manufacturing recover in North Carolina(current as of 10.17.24)
Baxter to Increase Allocations for IV Solution Supplies to Hospitals Effective Oct. 9
"Today on a call hosted by the Department of Health and Humans Services, Heather Knight, Baxter executive vice president and group president of medical products and therapies, announced that Baxter will be changing allocation for some IV solution supplies from 40% to 60% effective tomorrow, Oct. 9. In addition, Baxter expects to be at 70% by the end of October and 90% to 100% by the end of the year. We anticipate Baxter will notify customers later tonight or tomorrow, and we will provide updates as they become available. The AHA appreciates our ongoing partnership and collaboration with Baxter and HHS to help mitigate the impact to patients."
On 10.07.24, the American Hospital Association (AHA) sent a letter to President Biden urging certain actions be taken to, “…increase the supply of IV solutions for the nation’s hospitals, health systems, and other health care providers that are already struggling to provide care.”
The letter can be found here: AHA Letter to President Biden
Click on the image below to download our recommendations guide